The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Dyslipoproteinemia in systemic lupus erythematosus
Open accessAbstract
The increased incidence of atherosclerotic coronary artery disease in patients with systemic lupus erythematosus (SLE) may be due to a dyslipoproteinemia caused by corticosteroid administration. To determine whether lipoprotein lipid levels are abnormal in SLE and the relation of lipoprotein levels to corticosteroid use, lipid and apolipoprotein levels were measured in 46 female patients with SLE and 30 matched control subjects. The patients with SLE had higher levels of plasma triglyceride (134 versus 73 mg/dl; p less than 0.001), cholesterol (201 versus 168 mg/dl; p less than 0.001), and low-density lipoprotein cholesterol (121 versus 94 mg/dl; p less than 0.001) than control subjects. The levels of high-density lipoprotein cholesterol, high-density lipoprotein subfraction 3 cholesterol, and apolipoprotein Al were similar in the two groups, but high-density lipoprotein subfraction 2 cholesterol was lower in the patients with SLE (10.2 versus 18.2 mg/dl; p less than 0.001). When patients with SLE treated with prednisone (n = 32) were compared to patients with SLE not treated with prednisone (n = 14), the former had higher triglyceride (158 versus 87 mg/dl; p less than 0.001), cholesterol (214 versus 170 mg/dl; p less than 0.001), and low-density lipoprotein cholesterol (130 versus 103 mg/dl; p less than 0.001) levels. The patients with SLE not treated with prednisone had lipid levels similar to those in control subjects except that high-density lipoprotein cholesterol was lower (49.7 versus 59.0 mg/dl; p less than 0.05). The daily prednisone dosage in the treated patients with SLE correlated with levels of cholesterol (r = 0.38, p less than 0.02), high-density lipoprotein cholesterol (r = 0.40, p less than 0.02), and high-density lipoprotein subfraction 3 cholesterol (r = 0.47, p less than 0.01). Thus, female patients with SLE have a dyslipoproteinemia of the type that would place them at an increased risk for coronary artery disease. Corticosteroids, used in the treatment of SLE, seem to play a role in the pathogenesis of the observed lipoprotein abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A general cardiovascular risk profile: The Framingham study
Kannel, W. B., McGee, D., & Gordon, T. (1976) · The American Journal of Cardiology · doi:10.1016/0002-9149(76)90061-8 · Cited by 1,189
Cited by
Manzi, S., Meilahn, E. N., Rairie, J. E., Conte, C. G., Medsger, T. A., Jansen-McWilliams, L., D'Agostino, R. B., & Kuller, L. H. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009122 · Cited by 1,834
Risk factors for coronary artery disease in patients with systemic lupus erythematosus
Petri, M., Perez-Gutthann, S., Spence, D., & Hochberg, M. C. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90578-y · Cited by 624
Ward, M. M. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199902)42:2<338::aid-anr17>3.0.co;2-u · Cited by 529
Cardiac involvement in systemic lupus erythematosus
Doria, A., Iaccarino, L., Sarzi-Puttini, P., Atzeni, F., Turriel, M., & Petri, M. (2005) · Lupus · doi:10.1191/0961203305lu2200oa · Cited by 396
Cardiac Involvement in Systemic Lupus Erythematosus
Moder, K. G., Miller, T. D., & Tazelaar, H. D. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.3.275 · Cited by 297
Metadata
- Authors
- Ettinger, W. H., Goldberg, A. P., Applebaum-Bowden, D., & Hazzard, W. R.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 1987-09
- Volume
- 83
- Issue
- 3
- Pages
- 503-508
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W1557458006
- Cited by
- 191
- References
- 2
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dyslipoproteinemia in systemic lupus erythematosus. https://app.cochat.ai/papers/10.1016/0002-9343(87)90762-5
- The paper
- Ettinger, W. H., Goldberg, A. P., Applebaum-Bowden, D., & Hazzard, W. R. (1987). Dyslipoproteinemia in systemic lupus erythematosus. The American Journal of Medicine. https://doi.org/10.1016/0002-9343(87)90762-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.